Mitchell Kotler, MD
Urology · Linwood, NJNPI 1427057785
Payments from drug & device makers
Across 112 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$356
- Astellas Pharma US Inc$352
- Boston Scientific$294
- C. R. Bard, Inc. & Subsidiaries$173
- Neotract Inc.$170
- AbbVie$140
- plus $949 from 27 others
Across 1 payment — averaging $158.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$159
What the payments were for
- Food & beverage$2,38298%
- Education$522%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 4 | $356 |
| Astellas Pharma US Inc | 24 | $352 |
| Boston Scientific | 4 | $294 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $173 |
| Neotract Inc. | 6 | $170 |
| AbbVie(2 entities) | 11 | $140 |
| Endo Pharmaceuticals Inc. | 9 | $122 |
| Progenics Pharmaceuticals, Inc. | 1 | $95 |
| Coloplast | 6 | $85 |
| Aytu Biopharma, Inc. | 6 | $84 |
| Pfizer | 4 | $56 |
| Clarus Therapeutics Inc. | 3 | $42 |
| Acerus Pharmaceuticals Corporation | 3 | $39 |
| Johnson & Johnson | 3 | $38 |
| Antares Pharma, Inc. | 3 | $36 |
| Ambu Inc. | 2 | $33 |
| Clinigen, Inc. | 2 | $31 |
| Dentsply IH AB | 2 | $31 |
| Amgen | 2 | $30 |
| 180 Medical, Inc. | 1 | $27 |
| Myovant Sciences Inc. | 2 | $25 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Travere Therapeutics, Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $15 |
| Tolmar Pharmaceuticals, Inc. | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $14 |
| Cook Medical LLC | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $13 |
| Myriad Genetic Laboratories, Inc. | 1 | $13 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $13 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$326
- Bard Urinary Drainage Bag$157
- EMBOLD Fibered$150
- AMS$117
How this compares
$2,434 in reported general payments places this provider in the 50th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 236 | $214,575 |
| GemtesaVibegron | 97 | $96,594 |
| OrgovyxRelugolix | 13 | $34,647 |
| Mirabegron ErMirabegron | 32 | $23,026 |
| Tamsulosin Hcl | 901 | $18,767 |
| Solifenacin Succinate | 190 | $8,147 |
| Potassium Citrate ErPotassium Citrate | 57 | $6,774 |
| Finasteride | 426 | $6,547 |
| Testosterone | 12 | $4,790 |
| Silodosin | 26 | $3,388 |
| Methenamine Hippurate | 36 | $2,916 |
| Dutasteride | 58 | $2,214 |
| Tolterodine Tartrate ErTolterodine Tartrate | 18 | $1,702 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 17 | $1,442 |
| Tadalafil | 64 | $1,429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $352 | $214,575236 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 401 urology providers in New Jersey.
Other urology in Linwood
- Thomas MuellerLinwood$1.2M
- David SussmanLinwood$833K
- Gordon BrownCherry Hill$2.8M
- Nitin YerramHackensack$1.6M
- Michael StifelmanHackensack$1.5M
- Michael IngberDenville$607K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$464K
- Neil ShermanCranford$404K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.